Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $47.00 at Canaccord Genuity Group
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently weighed in on the company. Bank of […]
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently weighed in on the company. Bank of […]
